Gregory S. Patrick serves as Chief Financial Officer and VP Financial Operations for Sopherion Theapeutics, Inc. . Previously, Mr Patrick served for three years as Chief Financial Officer of MedImmune, a $6+ billion market cap, $1+ billion revenue biotechnology company. In this capacity, he was responsible for all finance, information technology, and corporate communications functions. Prior to joining MedImmune, Mr Patrick was Chief Financial Officer for Ventiv Health, a $300+ million market cap outsourced sales and marketing services company, where he led their spin out from Snyder Communications in 1999.

Mr Patrick also served as the initial Vice President and Controller of the Merck Manufacturing Division, holding that position for seven years. For a similar period of time, he held a variety of financial valuation positions at Merck, participating in the negotiation, structuring, and analysis of numerous licensing, joint venture, and business development initiatives. He previously held positions at Booz, Allen, and Hamilton, and Exxon Chemical Company.

Mr Patrick holds MBA in Finance, cum laude, from New York University. He previously earned BS and ME degrees in Environmental Engineering, cum laude, from Rensselaer Polytechnic Institute, with a minor in chemical engineering.